PFW Advisors LLC Has $209,000 Holdings in Boston Scientific Corporation $BSX

PFW Advisors LLC cut its holdings in Boston Scientific Corporation (NYSE:BSX) by 16.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,942 shares of the medical equipment provider’s stock after selling 378 shares during the period. PFW Advisors LLC’s holdings in Boston Scientific were worth $209,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BSX. Investment Management Corp VA ADV acquired a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $25,000. Sunbeam Capital Management LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $26,000. 1248 Management LLC acquired a new stake in shares of Boston Scientific in the first quarter valued at approximately $26,000. Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific in the first quarter valued at approximately $27,000. Finally, Ameriflex Group Inc. bought a new position in shares of Boston Scientific in the fourth quarter valued at $31,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at $18,659,923.46. This represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the company’s stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares of the company’s stock, valued at $1,959,328.37. This represents a 17.79% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 174,214 shares of company stock worth $18,397,457. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Stock Down 0.9%

Shares of NYSE BSX opened at $98.97 on Wednesday. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The company has a market cap of $146.65 billion, a price-to-earnings ratio of 58.91, a PEG ratio of 2.40 and a beta of 0.65. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50. The stock has a 50-day moving average price of $104.71 and a two-hundred day moving average price of $102.22.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business’s quarterly revenue was up 22.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on BSX shares. Leerink Partnrs raised shares of Boston Scientific to a “strong-buy” rating in a research note on Monday, June 16th. Wells Fargo & Company raised their target price on shares of Boston Scientific from $118.00 to $124.00 and gave the company an “overweight” rating in a research note on Thursday, July 24th. Truist Financial raised their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, July 24th. Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $118.00 to $125.00 in a report on Monday, September 8th. Finally, Jefferies Financial Group reissued a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Boston Scientific presently has an average rating of “Buy” and a consensus price target of $118.04.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.